K2–not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report.

Related Articles

K2–not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report.

J Med Toxicol. 2015 Mar;11(1):129-31

Authors: McKeever RG, Vearrier D, Jacobs D, LaSala G, Okaneku J, Greenberg MI

Abstract
INTRODUCTION: The adverse effects of synthetic cannabinoids are not well-described nor have they been thoroughly studied.
CASE REPORT: A 16-year-old male with a past medical history of asthma and attention deficit hyperactivity disorder (ADHD) presented to the emergency department (ED) complaining of 24 h of substernal pressure associated with dyspnea, nausea, and vomiting. He reported smoking tobacco cigarettes daily and occasional marijuana use but denied recent use of marijuana. The initial electrocardiogram (EKG) revealed ST-segment elevations in leads II, III, AVF, and V4-V6. The initial troponin level was reported as 1.47 ng/mL, and the initial creatine kinase MB (CKMB) level was 17.5 ng/mL. The patient admitted to smoking “K2” 60-90 min prior to the onset of symptoms. The patient manifested persistent ST elevations with a peak troponin of 8.29 ng/mL. The urine drug immunoassay was positive for benzodiazepines and opiates. Cardiac catheterization revealed normal coronary arteries, no wall motion abnormalities, and normal systolic function.
DISCUSSION: Synthetic cannabinoids may have significant potential adverse effects. Chest pain due to myocardial ischemia is rare in adolescents. When evaluating patients with chest pain, it is important to elicit a detailed drug history, specifically inquiring about synthetic cannabinoid use. Urine drug immunoassays may be unreliable and in this case did not detect synthetic cannabinoids.

PMID: 25154434 [PubMed – indexed for MEDLINE]

via http://www.ncbi.nlm.nih.gov/pubmed/25154434?dopt=Abstract